NIH R01 · 2025
Project Summary/Abstract In the >1,000,000 joint arthroplasties performed annually in the United States, ~5% will experience periprosthetic joint infection (PJI), with a 5 year mortality rate above 11%, (exceeding that of breast cancer, melanoma, and Hodgkin’s lymphoma). To prevent PJI, surgeons maintain stringent sterility in the operating theater, initiate prophylactic intravenous (IV) antibiotics at least 1 hour prior to surgery, ensure joint sterility with antiseptic lavage, and, depending on the center, may place 1-2 g of powdered vancomycin in the wound during closure. Bacterial survival and the ensuing potential for infection are attributed to formation of implant-adherent bacterial…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.